Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Onureg by Bristol-Myers Squibb for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Onureg by Bristol-Myers Squibb for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Onureg by Bristol-Myers Squibb for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase III for Diffuse Large B-Cell Lymphoma. According to...
Onureg by Bristol-Myers Squibb for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Onureg by Bristol-Myers Squibb for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Onureg is under clinical development by Bristol-Myers Squibb and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...